Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q1 2024 call → NOWe need to determine if management's forward account is substantially about narrating what its counterparties are themselves doing and scaling, such that the company's own volume is presented as a consequence of those parties' trajectories. Let's analyze the transcript. Management discusses several products: NanoKnife, Auryon, mechanical thrombectomy (AngioVac, AlphaVac), and Med Device (ports, etc.). The question is about whether management's forward story is a report on somebody else's expansion. Key points: For NanoKnife, they talk about the PRESERVE study, FDA submission, and market potential. They mention international growth and partnerships. But do they describe specific counterparties' own ramps? They mention "our international team continues to establish new relationships with partners who assist in supporting our procedures" – that's about their own efforts. They talk about physicians publishing data, but that's not a counterparty's business trajectory. They mention NICE upgrade in the UK, but that's a regulatory decision, not a counterparty scaling. For Auryon, they talk about placements and utilization, but that's their own sales and marketing. They mention "physicians are gaining confidence" – that's general demand. For mechanical thrombectomy, they talk about APEX PE study enrollment, and they mention "physician feedback" and "intuitive design" – again, their own product. For Med Device, they talk about ports growth and competition. The question specifically asks: does management narrate what its counterparties are themselves doing and scaling? Counterparties could be customers, partners, distributors, etc. In the transcript, management mentions "partners" in international markets, but they don't describe those partners' own expansion plans. They mention "key opinion leaders" and "scientific symposiums" – but that's about their own events. There is no specific mention of a particular customer or partner that is scaling up its own operations, and management is reporting on that as the driver. Instead, management talks about their own initiatives: clinical studies, product launches, sales training, etc. Thus, the answer is NO. The forward account is based on their own actions and market conditions, not on narrating counterparties' trajectories. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.